Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 336K | 617K | 558K | 989K | 0 |
| Gross Profit | 334K | 610K | -1M | 925K | -94K |
| Operating Income | -5M | -4M | -3M | -3M | -5M |
| EBITDA | -5M | -5M | -3M | -3M | -5M |
| Net Income | -5M | -5M | -3M | -4M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.062
+0.00% today
1Y Change
-20.90%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Provectus Biopharmaceuticals, Inc. (PVCT) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.06 and down 20.9% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -45.5%, EPS growth of -14.2%, a dividend yield of 0.0%. What stands out right now is revenue -45.5%, EPS -14.2%, free cash flow -1.3% with operating margin -1514.5% and ROIC 153.1%. Valuation already assumes a fairly strong business story at price/sales 71.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PVCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PVCT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PVCT Max Drawdown
-60.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PVCT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$5.5M
-55.9% YoY
Free Cash Flow
-$1.0M
+66.7% YoY
Revenue Growth
-45.5%
EPS Growth
-14.2%
Gross Margin
-13.7%
Net Margin
-1627.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 336K | 617K | 558K | 989K | 0 |
| Gross Profit | 334K | 610K | -1M | 925K | -94K |
| Operating Income | -5M | -4M | -3M | -3M | -5M |
| EBITDA | -5M | -5M | -3M | -3M | -5M |
| Net Income | -5M | -5M | -3M | -4M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 251K | 307K | 77K | 22K | 683K |
| Total Assets | 698K | 1M | 1M | 2M | 4M |
| Total Liabilities | 7M | 7M | 9M | 8M | 8M |
| Shareholder Equity | -6M | -6M | -8M | -6M | -4M |
| Total Debt | 3M | 3M | 3M | 2M | 2M |
| Net Debt | 3M | 3M | 3M | 2M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+66.7% YoY
Capital Expenditures
0
Free Cash Flow
1M
+66.7% YoY
Key ratios
Gross Margin
-13.7%
Operating Margin
-1514.5%
Net Margin
-1627.0%
ROE
93.3%
Debt / Equity
-0.47x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.